In the visual abstract, in footnote b under “Safety,” the percentage of patients in part D of the study (brentuximab vedotin and nivolumab) who had nausea or vomiting should be 14% each, not 4% each. The corrected visual abstract is shown below.
Skip Nav Destination
ERRATUM|
October 10, 2024
Friedberg JW, Bordoni R, Patel-Donnelly D, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024;143(9):786-795.
Blood (2024) 144 (15): 1647.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal